MedTrace Logo

Anlotinib for Hepatocellular Carcinoma

NCT04954521 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-07-08

No results posted yet for this study

Summary

The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment experience of a wide range of people.

Conditions

  • Liver Neoplasms

Interventions

DRUG

Anlotinib

This is an observational study

Sponsors & Collaborators

  • People's Hospital of Guangxi Zhuang Autonomous Region

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2023-07-05
Completion
2024-07-05

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04954521 on ClinicalTrials.gov